MMCM
NVAX icon

Murphy & Mullick Capital Management’s Novavax NVAX Stock Holding History

Murphy & Mullick Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50
Closed -$333 – 682
2025
Q2 		$333 Hold
50
– – ﹤0.01% 651
2025
Q1 		$321 Hold
50
– – ﹤0.01% 641
2024
Q4 		$402 Buy
+50
New +$482 ﹤0.01% 630

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Murphy & Mullick Capital Management's NVAX Position: Q3 2025 in Review

Murphy & Mullick Capital Management sold out of Novavax (NVAX) in Q3 2025, closing a stake of 50 shares — an estimated $333 sold.

Murphy & Mullick Capital Management first reported a position in NVAX in Q4 2024 and held it in 3 quarters. The position peaked at $402 in Q4 2024. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

  • Murphy & Mullick Capital Management reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 50 Novavax shares in Q3 2025, an estimated $333.
  • Murphy & Mullick Capital Management first reported a position in Novavax in Q4 2024 and held it in 3 quarters.
  • Murphy & Mullick Capital Management's Novavax position peaked at $402 in Q4 2024.
  • 249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Murphy & Mullick Capital Management's 13F filing for Q3 2025, filed 7 Nov 2025.